Arena Pharmaceuticals submits lorcaserin NDA to the FDA Arena Pharmaceuticals.

Based on the robust data package we submitted to the FDA, lorcaserin has the potential to meet this need, offering patients the opportunity to achieve sustainable weight reduction in a well-tolerated manner and improve their cardiometabolic health and standard of living.’ The pivotal Phase 3 clinical trial program, BLOOM and BLOSSOM , evaluated 7 nearly,200 patients treated for two years and showed that lorcaserin regularly produced significant weight loss with excellent security and tolerability.And new methods were derived for determining disease fighting capability targets of anti-HIV therapies, reducing HIV transmission through early treatment and identifying risk factors for coronary disease. Related StoriesBoston Children's Hospital selects Vijay G. Sankaran to receive Rising Star AwardStudy: Post medical center syndrome is significant risk factor for patients undergoing elective surgeryGlan Clwyd Medical center N Wales spend money on Esaote's G-Scan MRI device for weight-bearing scanningThe best prize was awarded for findings that early treatment with medications can prevent HIV transmitting.